Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia

Leukemia

Volumn 28, Issue 10, 2014, Pages 2005-2015

  Saulep Easton, D ^a   Vincent, F B ^a   Le Page, M ^a   Wei, A ^a,b   Ting, S B ^a,b   Croce, C M ^c   Tam, C ^d   Mackay, F ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c OHIO STATE UNIVERSITY   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD135 ANTIGEN; CYTOKINE; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; CPG ISLAND; CYTOLOGY; DENDRITIC CELL; DISEASE COURSE; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CPG ISLANDS; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERFERON-ALPHA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; MICE; TOLL-LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA;

EID: 84916231643     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.105     Document Type: Article

References (59)

1. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood 1974; 43: 789-795
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Modern Pathol 2000; 13: 193-207
3. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456
4. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009; 114: 2044-2050
5. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847
7. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112: 1923-1930
8. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009; 114: 4675-4686
9. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatmentresistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713-11718
10. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960
11. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033-2039
12. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Int Med 1998; 129: 559-566
13. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 2000; 75(10): 1039-1054
14. Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 99-104
15. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255
16. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Ann Rev Immunol 2011; 29: 163-183
17. Akbar AN. The silent war against CMV in CLL. Blood 2010; 116: 2869-2870
18. Yagci M, Ozkurt ZN, Yegin ZA, Aki Z, Sucak GT, Haznedar R. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010; 15: 240-244
19. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-135
20. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234: 142-162
21. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8() T cell accrual. Immunity 2010; 33: 955-966
22. Zhou LJ, Smith HM, Waldschmidt TJ, Schwarting R, Daley J, Tedder TF. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol 1994; 14: 3884-3894
23. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011; 208: 2367-2374
24. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011; 11: 34-46
25. Shodell M, Siegal FP. Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing. Scand J Immunol 2002; 56: 518-521
26. Munn DH, Mellor AL, Rossi M, Young JW. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005; 105: 2618
27. Maraskovsky E, Pulendran B, Brasel K, Teepe M, Roux ER, Shortman K et al. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv Exp Med Biol 1997; 417: 33-40
28. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878-884
29. Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SE. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol 1996; 157: 2953-2960
30. Ramsfjell V, Borge OJ, Cui L, Jacobsen SE. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34 CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997; 158: 5169-5177
31. Schroeder JT, Chichester KL, Bieneman AP. Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha. J Allergy Clin Immunol 2008; 121: 486-491
32. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-178
33. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-1219
34. Schiemann WP, Rotzer D, Pfeifer WM, Levi E, Rai KR, Knaus P et al. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev 2004; 28: 57-64
35. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009; 9: 365-370
36. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncology 2001; 19: 3611-3621
37. Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003; 17: 1973-1980
38. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-1226
39. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003; 33: 1633-1641
40. Picaud S, Bardot B, De Maeyer E, Seif I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002; 22: 457-462
41. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Nat Cancer Inst 1989; 81: 531-535
42. Ziegler-Heitbrock HW, Schlag R, Flieger D, Thiel E. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood 1989; 73: 1426-1430
43. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213
44. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-1725
45. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D et al. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8() T cells against exogenous viral antigens. Eur J Immunol 2006; 36: 2046-2060
46. Kranzer K, Bauer M, Lipford GB, Heeg K, Wagner H, Lang R. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 2000; 99: 170-178
47. Chen YL, Chen TT, Pai LM, Wesoly J, Bluyssen HA, Lee CK. A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. J Exp Med 2013; 210: 2515-2522
48. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-6487
49. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6: 2469-2473
50. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-5432
51. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 211-217
52. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010; 115: 5041-5052
53. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166: 2961-2969
54. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969-971
55. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23: 912-918
56. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-3377
57. Bonnefoy F, Couturier M, Clauzon A, Remy-Martin JP, Gaugler B, Tiberghien P et al. TGF-beta-exposed plasmacytoid dendritic cells participate in Th17 commitment. J Immunol 2011; 186: 6157-6164
58. Li L, Liu S, Zhang T, Pan W, Yang X, Cao X. Splenic stromal microenvironment negatively regulates virus-activated plasmacytoid dendritic cells through TGF-beta. J Immunol 2008; 180: 2951-2956
59. Seoane J. The TGFBeta pathway as a therapeutic target in cancer. Clin Transl Oncol 2008; 10: 14-19.